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Human peripheral blood lymphocytes (PBL) are acti-
vated to become suppressor T cells (S-T-C) by incubation 
with Concanavalin-A (Con-A). This has become the stan-
dard method for evaluation of suppressor function in 
patie~ts. S-T-C function has been found to be impaired 
in seve ral autoimmune diseases, including systemic lu-
pus erythematosus (SLE). Using this assay, we have 
investigated suppressor-cell function in 2 autoimmune 
disorders, bullous pemphigoid (BP) and pemphigus vul-
garis (PV), studying 6 patients from each group. Three 
patients with active SLE (positive controls), and 11 nor-
mal donors (negative controls) were also included. None 
of these patients had received systemic therapy with the 
exception of 2 patients with PV who were treated with 
gold in the past. PBL from the s e patients were incubated 
with and without 40 JLg/ml Con-A for 72 hr to generate 
suppressor ce lls. Both groups of PBL were then irradi-
ated with 1500 r cobalt. Co-cultures were s e t up in sex-
tuplicate using normal PBL as responders. Responder 
PBL were stimulated with 0.5, 1.0, and 2.0 JLg/ml of 
phytohemagglutin (PHA) and 5.0, 10.0, and 20.0 JLg/ml of 
Con-A. Cultures were pulsed on day 3 with ,jH-thymidine 
and harvested on day 4. Data were analyzed using Stu-
dent's t-test. S-T-C function was found to be significantly 
impaired in SLE vs normal (p=0.0316). No statistically 
significant difference was seen in BP (p=0.5883) and PV 
(p=0.0921) as compared with normals. A defect in sup-
pressor cell function may still be pres ent in patients with 
PV and BP for the defect may be antigen-specific and 
therefore r emain undetected by the Con-A suppressor 
assay. 
Bullous pemphigoid (BP) a nd pemphigus vulgaris (PV) ar e 
2 serious bullous dermatoses of unknown e tiology. The sera of 
these pa tien ts contain a utoa ntibodies [1,2] directed against 
antigens normally found on the slU-face of epidermal basal cells 
(BP) , a nd differ entiating keratinocytes (PV) . These a nt igens 
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Abbrevia tions: 
BMZ: basement membrane zone 
BP: bu llous pemphigoid 
Con-A: concanavalin A 
rcs: intracellulru' space 
IF: immunofluorescence 
JRA: juvenile rheumatoid rut hritis 
PBL: peripheral blood lymphocytes 
PHA: phytohemagglutin 
PV: pemphigus vu lgru'is 
SLE: systemic lupus erythematosus 
183 
are widely distributed in the skin of several other ver tebrate 
species [3]. Under normal conditions th e immune system is 
tolerant to these antigens; however, in pat ients with BP and 
PV, autosensitiza tion leads to the production of antiepidermal 
antibodies. The in vitro pathogenicity of PV [4-6J and BP [7-
8] autoa ntibodies h as been well doclUllented. 
A defect in the generation of suppressor T -cell activity in 
vitro has been found in patients with systemic lupus eryth e-
matosus (SLE) and juvenile rheumatoid artlu-i tis (JRA) 
[9-12]. This finding suggests that a similar defect could be 
present in ot her autoimmune diseases [13,14]' Therefore, it is 
conceiva ble, that in BP and P V there may be a decrease in th e 
activity of a n epidermal antigen-specific suppressor T -cell su b-
popula tion. An uncontrolled B-cell population may produce 
autoantibodies against the epidermal surface a ntigens, resul ting 
in disease. We found in this study using th e concanavalin -A 
induced suppressor assay, that in con trast to other au toimmune 
disorders such as SLE and JRA, no similar suppressor -cell 
defect was apparen t in patients wit h BP and PV. 
MATERIALS AND METHODS 
P atient Selection 
The diagnosis of BP was established in patients with subepidermal 
bullous eruptions and positive direct and indu'ect immunofl uorescence 
(IF) studies. PV was considered in those patients with intraepidermal 
bullous eruptions and positive dU'ect and indu'ect IF studies. The 
clinical featu.res of these patients ru'e seen in Table I. Patients with BP 
were studied while taking no steroids or immunosuppressive agents. 
Patients 1 and 3 in this group were studied on two occasions, both times 
prior to the administration of immunosuppre sive drug. From 6 pa-
tients wi th PV, 2 (patients 8 and 10) were in clinical remission for more 
than a yeru·. These patients were initially controlled with systemic 
steroids and immunosuppressive agents followed by gold therapy. No 
gold had been administered to these patients for 4 mo prior to our 
studies. Patients 7, 8, and 9 were studied on 2 occasions before systemic 
steroids were administered to control the disease. 
A group of 11 normal individuals among laboratory personnel and 3 
patients wi th active SLE was included in this study. Some c1inicoser-
ological features of the SLE patients are seen in Table II. Renal 
involvement was studied and scored as positive (+) or negative (-). A 
(+) renal involvement indicates that the e patients had an elevated 
creatinine clearance, proteinuria and an abnormal kidney biopsy. 
Immunofluorescent Techniques 
These techniques were performed as previously reported [15]. 
Concanavalin A (Con A) S uppressor Assay 
T he assay used in this investigation is similar to that originally 
described by Shou, Schwartz, and Good [16). Briefly, 30 tnl of venous 
blood was obtained and dilu ted wi th an equal volume of RPMI-1640 
(Flow Labs, Rockville, Md.) containing glu tamine, Hepes buffer, and 
gentamicin (Schering Corp., Keilworth, NJ). The mixture was spun 
over a ficoll-hypaque (Sigma, St. Louis, Mo. ) gradient and the lympho-
cytes were obtained fTom the interface, washed 3 times in Han~,'s 
balanced salt solution (HBSS), and resuspended in RPMI-1640 WIth 
20% fetal calf serum added. The concentration was adjusted to 3-5 x 
10-" celis/mJ. Half of the cell uspension was treated with Con-A, 40 
Mg/ml and half received no mitogen. After 3 days of incubation, the 
cells were washed in HBSS, resuspended in RPMI-1640 with 15% FCS 
at 1 X lO-(;/ ml and irradiated wi th a '''Cobalt source for a total dose of 
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1,500 rads. Parallel experiments showed that treatment of these cells 
with a-methyl-o-mannoside to remove a ny residual Con-A had no 
effec t on the stimulation of the second culture. Therefore, this reagent 
was not used routinally in other cultures. 
Responder lymphocytes were obtained from a norma l individual as 
above and suspended in RPMI-1640 with 15% FCS at a concentration 
of 1 X 10" cells/ml. To each well of a round-bottom microtite r plate 0.1 
ml of responder cells and either 0.1 ml of Con-A treated or untreated 
cells was added. All determinations were done in sextuplicate. The 
TABLE 1. Clinical and immunological features of patients with 
bullous pemphigoid and p emphigus vulgaris studied 
HI E Biopsy Direct IF Indirect IF 
Patient Sub- Intra-
cpider- epider- BMZ ICS BMZ ICS 
mal mal 
1 + IgG, C;j 
2 + IgG l:20 
3 + IgG , C" 1:10 
4 + IgG, C" 
5 + IgG, C" 1:160 
6 + IgG, C" U60 
7 + IgG, C;] 
8 + IgG, Ca" 1:10(*) 
9 + IgG 1:40 
10 + IgG , C/' 1:40(*) 
It + IgG 1:160 
12 + IgG 1:1280 
IgG 
"These tests were petformed during active phase of the disease. 
Con-A suppressor assay in these patients was performed when the 
disease was in clinical and serological remission for over a 12-mo period. 
TABLE U. SLE pa.tient8 
Patie nt LBT" CH,.o%" An ti DNA ANA Renal Involvement 
(U) (N :> 25%) 
1 IgM BMZ 26 80.3% 1:2560 + 
2 IgM BMZ 131 21.9% 1:640 + 
3 ND< 22 50.3% 1:160 
" Lupus band test. 
"Normal values for this laboratory range between 104-188 CH"o 
units. 
e ND: not done. 
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responder cells were then stimulated with either Con-A or phytohe-
magglutinin (PHA). After 3 days of incuba tion , the cells we re labeled 
with 0.02 mCi of ;jH thymidine for 18 hr and hru-vested on glass fiber 
filters with an automatic cell harvester the next day. The glass fiber 
discs were counted in a beta scintillation counter. 
The percent of suppression was derived by the formula below: 
% Suppression = 
1 -
mean CPM of stimulated 
cultures containing 
Con-A activated cells 
mean CP M of stimulated 
cultures containing 
non-activated cells 
mean CPM of 
unstimu lated cells containing 
Con-A activated cells 
mean CPM of unstimu la ted 
cultures containing 
non-activated cells 
Sta tistical analysis of these values was done by Student's I-test p 
values ~ 0.05 were considered significant. 
RESULTS 
The results of the suppressor assays for each group of patients 
and controls are shown in Tables III-VI. The results are ex-
pressed in pel'cent suppression for each dose of mitogen. The 
mean standard deviations for each dose are also included. The 
amount of stimulation in our cultures is comparable to that 
previously published reports [9-12). 
Table VII displays the results of statistical analysis by Stu-
dent's t-test of normals versus disease groups. These are also 
shown for each dose of mitogen used in the assay. The sup-
pression va lues in the PV and BP groups showed no statistically 
significant differences with the control group, while there were 
significant differences between the controls and the SLE gl'OUp. 
The failure to generate suppressor activity in the PBL from 
patients with SLE is consistent with previous reports [12,13] 
and contrasts sharply with the Con-A induced suppressor activ-
ities manifested by PBL from BP and PV patients. 
DISCUSSION 
It is known that patients with P V and BP become sensitized 
to epidermal cell surface antigens. This autosensitization leads 
to the production of autoantibodies which are highly specific 
for squamous epithelia. Whether tolerance to these epidermal 
cell surface antigens is actively maintained by antigen-specific 
suppressor T cells in the normal state is unknown. It is conceiv-
TABLE III. Suppression of mitogenesis by allogeneic Con-A activated supressor cells from. normal clonors 
Percent supp" ession in II donors 
Mitogen 2 3 4 5 6 7 8 9 10 1I Mean Ilg/ml ±SD" 
PHA 0.5 4.31 38.4 38.5 45.3 33.8 77.7 5.9 4 1.5 43.9 64 .4 81.3 46.7 ± 2].1. PHA 1.0 26.7 27.9 27.6 31.4 26.7 70.8 47 .5 21.2 36.3 38.9 G3.0 38.0 ± 16.1 
PHA 2.0 21.4 27.9 29.5 35.8 15.2 42.5 39.4 32.6 35.0 26.9 44.8 31.9 ± 8.9 Con-A 5.0 27.3 50.6 30.8 49.0 40.3 22.8 55.6 32.2 61.1 55.5 43.6 42.6± 12.9 Con-A 10.0 25.9 51.4 26.1 37.7 36.2 39.8 70.9 20.3 43.6 :35.5 44.3 38.7 ± 14 .1 Con-A 15.0 ND" ND ND ND 32.2 50.3 72.2 21.5 55.1 ND ND 46.2 ± 19.9 Con-A 20.0 20.2 57.6 26.2 35.4 ND ND ND ND ND 59.3 42.5 40.2 ± 16.1 
" SD: standard deviation . 
" ND: not done. 
TABLE IV. S uppression of mitogenesis by allogeneic Con. -A activated supressor cells from bullolls pemphigoid patients 
Mitogen 
Ilg/ m1 
PHA 0.5 
PHA 1.0 
PHA 2.0 
Con-A 5.0 
Con-A 10.0 
Con-A 15.0 
Con-A 20.0 
40.8 
50.6 
43.0 
67.5 
83.0 
ND" 
77.8 
" SD: standard deviation. 
" ND: not done. 
2 
24 .0 55.6 
20.0 33.0 
11.2 26.1 
9.2 10.1 
24 .8 16.2 
49.9 ND 
ND 14.1 
Percent suppression in 6 patients 
3 3 
56.3 41.9 
32.9 21.4 
19.6 48.5 
68.1 37.4 
29.3 2.4 
40.1 ND 
ND 40.0 
5 6 Mea n 
±SD" 
46.0 74.2 73.9 51.6 ± 17. 1 
23.5 62.8 80.7 40.6 ± 22. 1 
28.3 51.6 68.7 37.1 ± 19. 1 
39.8 51.3 39.9 40.4 ± 22.4 
33.7 62.9 47.2 37.4 ± 2G.0 
ND 62.2 82.5 58.7 ± 18.3 
42.2 ND ND 43.5 + 26.2 
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TABLg V. Suppression of mitogenesis by allogeneic Con -A activated suppressor cells from pemphigus vlllgaris patients 
Percent suppres..,ion in (j PIt icnt.s 
Mitogen 
Mean ± SD" I'g/ mi 7 7 8 8 9 9 10 II 12 
PHA 0.5 35.7 34.6 13.3 17.6 ND ND 1.2 43.5 66.2 30.3 ± 21.6 
PHA 1.0 26.1 23.7 17.0 25.5 39.5 44 .6 12.8 24.9 35.9 27.8 ± 10.4 
PHA 2.0 22.9 22.6 15.0 19.1 17.4 38.0 7.2 27.5 37.6 23.0 ± 10.1 
PHA 4.0 NO" ND ND ND 38.8 32.6 ND ND ND 35.7 ± 4.4 
Co n-A 5.0 22.2 21.3 19.3 35.1 40.2 40.4 18.0 39.4 64.4 33.4 ± i5.0 
Con-A 10.0 27.1 26.6 27.9 55.0 21.0 57.8 59.4 28.9 47.7 39.0 ± 15.6 
Con-A 15.0 ND ND ND 43.9 ND ND ND NO NO (ND) 
Con-A 20.0 33.5 32.5 30.5 ND 41.7 68.7 64.1 30.1 52.7 44 .2 ± 15.6 
" SD: standard deviation. 
/, N D: not done. 
TABLE VI. Suppression of mitogenesis by a.llogeneic Con-A 
activated suppressor cells from LE patients 
Mit.ogen Percent suppression in 3 Plltienl.R Melin 
Ilg/ mi 2 3 ± Dn 
PHA 0.5 17.3 15.2 21.5 18 ± 3.2 
PHA 1.0 20.9 (-5.3) (- 0.)0) 5.2 ± 13.9 
PHA 2.0 18.9 (-1.7) (-5.8) 3.8 ± 13.2 
Con-A 5.0 (-3.9)/' 17.6 (-5. l) 2.9 ± 12.8 
Con-A 10.0 14.7 . 28.9 12.6 18.7 ± 8.9 
Con-A 20.0 16.6 0.8 14.9 10.8 ± 8.7 
" SD: stand81'd deviation. 
/, (-) denotes enha ncement of mitogenesis above 100%. 
TABLE VII . P-Va. lues from Student's t·test n.onnal versus disease 
Mitogen Il!;/ tni Pemphigoid Pemphi!;us SLE n =8 n = 8 n =3 
PHA 0.5 NS" NS 0.0418 
PHA 1.0 NS NS 0.0076 
PHA 2.0 NS NS 0.0008 
Con-A 5.0 NS NS 0.0005 
Con-A 10.0 NS N 0.0405 
Con-A 15.0 NS NS ND/ 
Con-A 20.0 NS NS 0.0230 
" NS: not significant. 
/, N D: not done. 
able, therefore, that patients with I V and BP may lack such a 
population of antigen-specific suppre sor cells. 
It has been shown [16] that incubation of PBL from normal 
individuals with Con-A generates a population of suppressor 
lymphocytes in vitro. The suppressor activity is expressed as 
the percentage of inhibition (or suppression) induced by these 
cells on cultures of mitogen-stimulated normal lymphocytes, by 
both PHA and Con-A. This assay has become widely used in 
the evaluation of suppressor cell function in vitro. The mitogens 
PHA and Con-A were used because they stimulate a broad 
range of lymphocytes. Suboptimal, optimal and supraoptimal 
doses of each mitogen were tested in order to detect minimal 
defects in suppressor activity. Several studies recently reported 
have shown that generation of suppressor cells from PBL from 
patients with active SLE or JRA by Con-A is deficient [9-12J, 
suggesting that this defect may play an important role in the 
pathogenesis of these and other autoimmune diseases. 
This investigation has shown that the generation of suppres-
sor cell function by Con-A in PBL of 6 patients wit.h BP and 6 
patients with PV fell within the range of response of 11 normal 
individuals. Three cases of active SLE, however, included as a 
positive control group showed a markedly depressed suppressor 
cell function as compared with the normal control group. All 
patients tested were receiving no medications, although 2 pa-
tients with PV were in clinical and serological remission for 
more than a year. The remainder of the patients studied were 
clinjca lly and serologically active. The normal values of Con-A 
suppressor function detected in the PBL of PV and BP may 
have resulted [Tom the insensitivity of 311TDR incorporation as 
a measure of lym phocyte function , with small shifts in lymp ho-
cyte subpopulations remaining undetected. If PV and BP are 
antigen-specific autoimmune diseases, the loss of regulatory 
suppressor cells to these antigens would be negligible as com-
pared to the broad spectrum of lymphocyte regulatory activi-
ties. It is feasible that such a minimal deviation may not be 
recognized by this assay. In SLE, there is a more generalized 
loss of suppressor cell function, and it is easily recognized by 
this assay. Studies testing this possibility are currently under 
investigation. 
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